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and medical environment for patient suffering from 
psoriasis.
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Psoriasis has a heavy impact on the physical and mental
well-being of the patient, especially when the areas
affected are visible to others. Do women affected by pso-
riasis suffer more than men in this respect? OBJECTIVE:
To evaluate the quality of life level of patients with 
psoriasis according to gender. METHOD: Within the
context of the SPOT study, 542 patients (298 men/244
women) responded to a qol questionnaire consisting of a
generic scale (SF-12) and a speciﬁc scale (PDI–Psoriasis
Disability Index). The completed questionnaires were
returned in prepaid envelopes. RESULTS: The socio-
demographic proﬁle of the patients in the two groups did
not present any statistically signiﬁcant difference The
mean age was respectively 46.3 years for the men versus
44.6 years for the women. The PDI score was 11.9% (SD
= 11.7) for the men and 14.8% (SD = 14.4) for the
women; the difference was statistically signiﬁcant (p =
0.031). For the Work, Social relations, Leisure and Treat-
ment dimensions, no difference was observed between the
two sexes: respectively 6.8% (SD = 13.6), 13.0% (SD =
19.4), 12.5% (SD = 16.5), 11.6% (SD = 18.2) in men
versus 7.9% (SD = 15.2), 14.7% (SD = 23.1), 14.1% 
(SD = 18.2), 11.8% (SD = 20.6) in women. On the other
hand, for the Daily Activities dimension the score was
14.0% (SD = 13.3) for the men and 19.9% (SD = 18.4)
for the women. The difference was statistically signiﬁcant
(p < 0.0007). With regard to the SF-12, the results were
organised in 2 scores: mental (MCS-12) and physical
(PCS-12). The scores for the men were: PCS-12 = 51.3
(SD = 7.6) & MCS-12 = 43.4 (SD = 10.0). The scores 
for the women were: PCS-12 = 51.6 (SD = 7.9) & 
MCS-12 = 40.1 (SD = 11.3). With regard to the mental
dimension, the difference was statistically signiﬁcant 
(p < 0.0005). CONCLUSION: Psoriasis modiﬁes the
quality of life more greatly for women, who suffer more
than men. This is especially true for the mental dimen-
sion (SF12) and for the daily activities dimension as
shown by the PDI.
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By deﬁnition, dermatological pathologies have an effect
on one’s self-image, and this may lead to severe psycho-
logical troubles. OBJECTIVES: To evaluate depressive
symptomatology–DS-in patients suffering from chronic
dermatosis. To evaluate the effect of chronic dermatosis
on depressive symptomatology in France for patients
going to a medical consultation at Saint Louis Hospital
(Paris—France). METHODS: The CES-D was remitted to
every patients entering any dermatological consulting
room at Saint Louis Hospital. Two groups were identi-
ﬁed: population coming to a speciﬁc and thematic
doctor’s visit (psoriasis, atopic dermatitis, . . .)—usual
visits or patients coming to the “consultation porte”
(doctor visits without any appointment and taking care
of more distressed dermatological diseases). RESULTS:
The “consultation porte” represents around 22% of the
doctor’s visits versus 78% for the usual visits visits. In 
the studied population (n = 774), 23.6% of the patients
reported depressive symptomatology (CES-D+) whereas
76.4% did not (CES-D-). For patients coming to the
“consultation porte” CES-D+ population represents
31.4% (n = 172) vs 21.4% in the patients having usual
visit (n = 602). As shown, depressive symptomatology is
more often reported for patient coming to the “consulta-
tion porte” compared to patients coming to the usual
visits. This difference is statistically signiﬁcant (test Chi 2
p < 0.01). If we compare the depressive symptomatology
incidence according to dermatological disease, the results
are the following: psoriasis 19%, atopic Dermatitis 28%,
acne 32, and nævi 13%. CONCLUSION: These results
thus give us an idea of both the extent and the impor-
tance of the psychological impact that dermatological 
diseases usually generate. Global disease management
together with psychological support therefore seems
essential for patients suffering from chronic dermatosis.
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OBJECTIVES: To assess the impact of psoriasis vulgaris
treatment with tacalcitol on quality of life. METHODS:
An epidemiological, observational, prospective and mul-
ticenter study of a cohort of patients with mild to mod-
erate Psoriasis vulgaris has been performed. Patients have
been treated with tacalcitol ointment (4mg/g). Anthro-
pometric and demographic characteristics of patients
were recorded in addition to percentage of affected area
and previous and current treatments. Symptomatology
(erythema, desquamation and thickness) was evaluated
by a scale from 0 (absent) to 4 (maximum intensity of
symptom). At follow-up (15 and 60 days) symptomatol-
ogy and appearance of adverse effects were registered.
